Oesophageal Doppler Monitoring specialist Deltex Medical Group plc says its wholly owned UK subsidiary, Deltex Medical Limited, has been awarded a grant by Innovate UK, to further develop its ‘TrueVue’ haemodynamic monitoring platform.
Deltex Medical tells us its Oesophageal Doppler Monitoring(ODM) system is clinically proven in numerous randomised controlled trials to improve patient outcomes, reduce mortality and reduce healthcare costs. The company claims its technology delivers uniquely accurate, real-time pressure and flow data direct from the aorta which can guide anaesthetic care to keep the patient in the so-called haemodynamic sweet spot that will optimise perfusion of the vital organs during and after surgery.
Recognising the demand for monitoring in different clinical settings, particularly in the awake patient, Deltex recently broadened its offering to include what it says are best-in-class alternative modes. The platform was rebranded as TrueVue and designed for all patients from newborn to adult, anaesthetised or awake and across all hospital settings. It is for further development of the TrueVue system that Deltex has now been awarded the new grant. Innovate UK is part of UK Research and Innovation, which is funded by the UK government and works in partnership with universities, research organisations, businesses, charities and government to create the best possible environment for research and innovation to flourish.
The total eligible project costs are £500,000, of which 70% (£350,000) will be reimbursed by Innovate UK with the balance funded from the Group’s operating activities over the estimated eighteen month project.
This Innovate UK Smart Award is the largest of five grants that Deltex Medical Limited has been awarded so far this year to enhance the Group’s unique range of haemodynamic monitoring technologies.
Andy Mears, Deltex Medical’s CEO, commented: “I am very pleased that we have been successful in winning this prestigious Innovate Smart Award.
The award of five grants this year helps to highlight the commercial and technological potential for Deltex Medical’s unique range of haemodynamic monitoring technologies.”
Source: Deltex Medical